Serum Institute of India to launch indigenously made vaccine to treat cervical cancer

Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenouslydeveloped vaccine to treat cervical cancer in women later this year. The Drugs Controller General of India (DCGI) on Tuesday granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. In response to the approval by the drug regulator, Poonawalla in a tweet said, "For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA for granting approval today." The approval by the drug regulator of SII's anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15. The company had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!